Evidence map›Paper›PMID 8857853›Full record

SynthesisAnnals of surgery1996

Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials.

H Buchwald, C T Campos, J R Boen, P Nguyen, S E Williams, J Lau, T C Chalmers

Registry-linked trialOpen access · greenAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of surgery, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00000490 (Program on Surgical Control of Hyperlipidemias), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000490 phase3completednot on this map

Program on Surgical Control of Hyperlipidemias (POSCH)

TypeinterventionalSponsorUniversity of MinnesotaRan1973 to 1997ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial InfarctionArmsjejunoileal bypass, diet, fat-restricted
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

H BuchwaldDepartment of Surgery, University of Minnesota, Minneapolis, USA.
C T Campos
J R Boen
P Nguyen
S E Williams
J Lau
T C Chalmers
Twin Cities Orthopedics · USUniversity of Minnesota · USHarvard University Press · USIndian Institute of Technology Roorkee · INTufts University · US

Funding

SURGICAL CONTROL OF THE HYPERLIPIDEMIASR01HL015265 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BUCHWALD, HENRY · 1985 to 1991
–
POSCH--LONG-TERM MORTALITY AND MORBIDITYR01HL049522 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BUCHWALD, HENRY · 1993 to 1997
–
NHLBI NIH HHS R01-HL-15265NHLBI NIH HHS R01-HL-49522
6 · The paper itself

Abstract

objectiveThe authors assessed the clinical results of lipid-lowering therapy in women. SUMMARY BACKGROUND DATA: The Program on the Surgical Control of the Hyperlipidemias (POSCH) has demonstrated that effective lowering of total cholesterol and low-density lipoprotein cholesterol in a postmyocardial infarction population significantly reduces atherosclerotic coronary heart disease (ACHD) mortality, ACHD mortality combined with a new confirmed nonfatal myocardial infarction, and the number of coronary artery bypass grafting and angioplasty procedures performed.

methodsA review and meta-analysis were performed of the seven primary or secondary lipid/ atherosclerosis intervention trials-including POSCH-published in the English-language literature that included women and published results in women separate from the results in men or in the entire trial population. The main outcome measure analyzed was overall mortality.

resultsThe Scottish Physicians Clofibrate Study, the Newcastle upon Tyne Clofibrate Study, and the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I) Trial may have demonstrated a possible benefit in ACHD prognosis from effective lipid intervention in women. The other four available trials did not. The Minnesota Coronary Survey reported a 15.6% increase in overall mortality rate and a 30.6% increase in a combined cardiovascular endpoint rate in the lipid-intervention group. The Upjohn Colestipol Study demonstrated statistically significant reductions in overall and ACHD mortality in the men, but not in the women. The Scandinavian.

Indexed as

CholesterolControlled Clinical Trials as TopicCoronary Artery DiseaseFemaleHumansHyperlipidemiasHypolipidemic AgentsIleumMaleRisk FactorsSurvival RateCholesterolHypolipidemic Agents

Identifiers

PMID8857853
PMCPMC1235410
OpenAlexW2054236661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.